Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-4-19
pubmed:abstractText
Pancreatic ductal adenocarcinoma (PDAC) represents the eighth frequent solid tumor and fourth leading cause of cancer death. Because current treatments against PDAC are still unsatisfactory, new anticancer strategies are required, including oncolytic viruses. Among these, autonomous parvoviruses (PV), like MVMp (minute virus of mice) and H-1PV are being explored as candidates for cancer gene therapy. Human PDAC cell lines were identified to display various susceptibilities to an infection with H-1PV. The correlation between the integrity of the transcription factor SMAD4, mutated in 50% of all PDAC, and H-1PV permissiveness was particularly striking. Indeed, mutation or deletion of SMAD4 dramatically reduced the activity of the P4 promoter and, consequently, the accumulation of the pivotal NS1 protein. By means of DNA affinity immunoblotting, novel binding sites for SMAD4 and c-JUN transcription factors could be identified in the P4 promoter of H-1PV. The overexpression of wild-type SMAD4 in deficient cell lines (AsPC-1, Capan-1) stimulated the activity of the P4 promoter, whereas interference of endogenous SMAD4 function with a dominant-negative mutant decreased the viral promoter activity in wild-type SMAD4-expressing cells (Panc-1, MiaPaCa-2) reducing progeny virus production. In conclusion, the importance of members of the SMAD family for H-1PV early promoter P4 activity should guide us to select SMAD4-positive PDACs, which may be possible targets for an H-1PV-based cancer therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1097-0215
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2914-27
pubmed:dateRevised
2010-6-16
pubmed:meshHeading
pubmed-meshheading:19856310-Adenocarcinoma, pubmed-meshheading:19856310-Carcinoma, Pancreatic Ductal, pubmed-meshheading:19856310-Gene Expression Regulation, Neoplastic, pubmed-meshheading:19856310-Genetic Vectors, pubmed-meshheading:19856310-H-1 parvovirus, pubmed-meshheading:19856310-Humans, pubmed-meshheading:19856310-Luciferases, pubmed-meshheading:19856310-Mutation, pubmed-meshheading:19856310-Pancreatic Neoplasms, pubmed-meshheading:19856310-Parvoviridae Infections, pubmed-meshheading:19856310-Prognosis, pubmed-meshheading:19856310-Promoter Regions, Genetic, pubmed-meshheading:19856310-RNA, Messenger, pubmed-meshheading:19856310-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19856310-Smad4 Protein, pubmed-meshheading:19856310-Transfection, pubmed-meshheading:19856310-Tumor Cells, Cultured, pubmed-meshheading:19856310-Tumor Markers, Biological, pubmed-meshheading:19856310-Viral Nonstructural Proteins, pubmed-meshheading:19856310-Virus Replication
pubmed:year
2010
pubmed:articleTitle
SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
pubmed:affiliation
Abt F010, Infection and Cancer Program, Tumor Virology Division, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, Heidelberg, Germany
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't